Current price is more than the intrinsic value

Intrinsic value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Eris Lifesciences recently acquired nine brands from Glenmark, consisting of derma portfolio for Rs 340 crore, with topmost brands having a leadership position in the pharmaceutical market

What is driving growth for pharma major Eris Lifesciences?

Motilal Oswal is bullish on Eris Lifesciences recommended buy rating on the stock with a target price of Rs 780 in its research report dated January 18, 2023.

Buy Eris Lifesciences; target of Rs 780: Motilal Oswal

Eris Lifesciences announced acquisition of nine dermatology brands from Glenmark Pharma for Rs 340 crore. The brands include Onabet, Halobate, Sorvate, and Demelan for India and Nepal.

Eris Lifesciences falls as margins contract; derma brands’ acquisition fails to cheer Street

Acquisition of Oaknet and Glenmark Pharma’s derma portfolio to strengthen Eris’s entry in the derma segment.

Eris Lifesciences Q3 Results Review - Inline Quarter; New Launches Scale-Up Is Key: Prabhudas Lilladher

The nine brands have sales of Rs 87.30 crores for FY22, which represents valuation of 3.9x of the sales of these brands in FY22. The acquired brands include antifungals Onabet, Luligee; topical steroids Halovate, Sorvate, Dosetil and Powercort, demelanising agent Demelan, vitamin-A gels - Aceret.

Eris buys nine derma brands from Glenmark for Rs 340 crore

Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 850 in its research report dated January 18, 2023.

Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher

Eris Lifesciences’ consolidated net profit rose marginally to Rs 101.86 crore in Q3 FY23 as against Rs 100.77 crore recorded in Q3 FY22.

Eris Lifesciences records PAT of Rs 102 cr in Q3 FY23

Buzzing stocks: Central Bank of India, RVNL, ITC, EID Parry, Berger Paints, Glenmark Pharma, Eris Lifesciences, South Indian Bank, SAIL, LIC, COforge, Sundaram Fasteners, IndusInd Bank, Goa Carbon, Alok Textiles

Stocks that will see action on January 18, 2023

ERIS Lifesciences consolidated net profit rises 1.08% in the December 2022 quarter

The deal, through Eris’ dermatology focused unit, is for the purchase of nine brands, including Onabet, Halobate, Sorvate, and Demelan for India and Nepal, Eris said.

Eris Lifesciences to buy some dermatology brands from Glenmark Pharma

Glenmark to divest Tail Brands from its dermatology segment for India and Nepal territories

Eris Lifesciences Limited is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market

Eris Lifesciences Ltd

Eris Lifesciences Ltd

Intrinsic value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

What is driving growth for pharma major Eris Lifesciences?

Buy Eris Lifesciences; target of Rs 780: Motilal Oswal

Eris Lifesciences falls as margins contract; derma brands’ acquisition fails to cheer Street

Eris Lifesciences Q3 Results Review - Inline Quarter; New Launches Scale-Up Is Key: Prabhudas Lilladher

Eris buys nine derma brands from Glenmark for Rs 340 crore

Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher

Eris Lifesciences records PAT of Rs 102 cr in Q3 FY23

Stocks that will see action on January 18, 2023

Eris Lifesciences Ltd

Intrinsic valueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry pointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

What is driving growth for pharma major Eris Lifesciences?

Buy Eris Lifesciences; target of Rs 780: Motilal Oswal

Eris Lifesciences falls as margins contract; derma brands’ acquisition fails to cheer Street

Eris Lifesciences Q3 Results Review - Inline Quarter; New Launches Scale-Up Is Key: Prabhudas Lilladher

Eris buys nine derma brands from Glenmark for Rs 340 crore

Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher

Eris Lifesciences records PAT of Rs 102 cr in Q3 FY23

Stocks that will see action on January 18, 2023

Intrinsic value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock